Citations

Clear

6274 citation(s) found for "To, Andrew".

509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
Callahan, Margaret K. , Costello, Brian A. , Curti, Brendan D. , Hansen, Aaron R. , Long, Georgina V. , Shankles, Brooke, Ulge, Umut Y. , Weickhardt, Andrew , Long, Georgina V , Hansen, Aaron R , Naing, Aung , Hall, Evan , Joshua, Anthony M.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A540-A540

10.1136/jitc-2021-sitc2021.509 Get It

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer
Brendel, Karl , Bekaii‐Saab, Tanios , Dayyani, Farshid , Dean, Andrew , Macarulla, Teresa , Maxwell, Fiona , Mody, Kabir , Pedret‐Dunn, Anna, Dayyani, Farshid , Bekaii-Saab, Tanios S , Macarulla, Teresa , Boland, Patrick M. , Wainberg, Zev A. , Zhang, Bin

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | November 9, 2021 | Volume: 10 | Issue: 12 | Pages: 1550-1563

10.1002/psp4.12725 | PMID 34750990 Get It

AbstractLiposomal irinotecan is a liposomal formulation of irinotecan, which prolongs circulation of irinotecan and its active metabolite SN‐38. A population pharmacokinetic (PK) model was developed based on data from seven studies (N = 440). Adequacy of the model was assessed using multiple methods, including visual predictive check. Associations between PK exposure and the incidence of diarrhea (grade ≥3) and neutropenia adverse events (AEs) (grade ≥3) at first event in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) were investigated using logistic regression based on data from two studies (the phase III NAPOLI‐1 [N = 260] and phase I/II NCT02551991 [N = 56] trials). The PKs of total irinotecan was described by a two‐compartment model with first‐order elimination, with SN‐38 formed directly by a first‐order constant from the central compartment of irinotecan or after using a transit compartment. Clearance was 17.9 L/week (0.107 L/h) and 19,800 L/week (118 L/h) for total irinotecan and SN‐38, respectively. The UGT1A1*28 7/7 homozygous genotype had no significant impact on SN‐38 clearance. Model evaluation was satisfactory for both irinotecan and SN‐38. The incidence of diarrhea (grade ≥3) at first event was significantly higher with increasing average concentrations of total irinotecan and SN‐38; there was no significant association between an increased risk of neutropenia AEs (grade ≥3) at first event and average SN‐38 concentrations. In summary, the PKs of total irinotecan and SN‐38 after administration of liposomal irinotecan were well‐described by the model. The UGT1A1*28 status had no significant impact on the PKs of liposomal irinotecan.
Risk of hydroxychloroquine retinopathy in the community
Dabit, Jesse Y. , Hocaoǧlu, Mehmet , Moder, Kevin G., Smith, Wendy M. , O’Byrne, Thomas J., Crowson, Cynthia S. , Duarte‐García, Alí , Duarte-García, Alí , Barkmeier, Andrew J.

Mayo Clinic

Rheumatology | November 8, 2021 | Volume: 61 | Issue: 8 | Pages: 3172-3179

10.1093/rheumatology/keab844 | PMID 34788400 Get It

Abstract Objectives We aimed to estimate the risk of HCQ retinopathy and its risk factors among incident users in the community. Methods Using the Rochester Epidemiology Project, a record-linkage system, a cohort of incident users of HCQ was identified from 27 counties in the American upper Midwest. HCQ retinopathy was defined based on characteristic paracentral automated 10-2 visual field (10-2 AVF) defects and parafoveal retinal photoreceptor layer changes on spectral domain optical coherence tomography. Cumulative incidence rates were estimated adjusting for competing risk of death. Risk factors for HCQ retinopathy were examined using Cox models. Results The study included 634 incident HCQ users (mean age at initial HCQ use was 53.7 years, 79% females, 91% white). Most common indications for HCQ were RA (57%) and SLE (19%). The average follow-up length was 7.6 years. Eleven patients developed HCQ retinopathy (91% females, 91% white). The majority used HCQ for RA (91%). The cumulative incidence rate at year 5 was 0%, which increased to 3.9% (95% CI 2.0, 7.4) by 10 years. Taking an HCQ dose ≥5 mg/kg was associated with a hazard ratio (HR) of 3.59 (95% CI 1.09, 11.84) compared with lower doses. There was a 48% increase [HR 1.48 (95% CI 1.03, 2.14)] in the risk of HCQ retinopathy for each 100 g of HCQ cumulative dose. Conclusion The risk of HCQ retinopathy at 10 years of use is lower compared with previous prevalence-based estimations. A dose ≥5 mg/kg was associated with higher HCQ retinopathy risk.
Extracorporeal membrane oxygenation in the forensic setting: A series of 19 forensic cases
Layman, Andrew J. , Lin, Peter T. , Layman, Andrew J.

Mayo Clinic

Journal of Forensic Sciences | November 6, 2021 | Volume: 67 | Issue: 1 | Pages: 243-250

10.1111/1556-4029.14918 | PMID 34741312 Get It

AbstractExtracorporeal membrane oxygenation (ECMO) employs vascular cannulation and a gas exchange circuit to provide support to patients with severely compromised cardiopulmonary function. ECMO is often the last intervention taken before death and thus presents a unique challenge to medical examiners. This study describes the characteristics of decedents on ECMO at the time of death, including clinical indications, types of circuit configurations, causes and manners of death, gross findings at autopsy, and therapeutic complications. Files of a regional medical examiner office within an academic medical center were searched for the period between 2013 and 2019. Nineteen cases were identified with a median age of 36 years. The circumstances surrounding the initial presentation included: sudden death, trauma, substance abuse, homicide, therapeutic complication, work‐related injury, drowning, and hypothermia. The underlying causes of death included injury‐related, as well as respiratory and cardiac‐related natural diseases. The time spent on ECMO varied from less than 1 h to 10 months. Complications encountered due to ECMO included cannulation site bleeding, pneumohemopericardium, retroperitoneal hematoma, limb ischemia, clotting, and cannula dislodgement. The patient population likely to receive ECMO has significant overlap with death circumstances likely to be reported to the medical examiner. As ECMO therapy has become increasingly available, it is of importance for medical examiners and death investigators to be familiar with the procedure as well as its limitations. Familiarity with ECMO and its sequelae allows for the proper documentation of postmortem findings and fosters an informed determination of the cause and manner of death.
Hypoglycemic and Hyperglycemic Crises Among U.S. Adults With Diabetes and End-stage Kidney Disease: Population-Based Study, 2013–2017
Galindo, Rodolfo J. , Ali, Mohammed K. , Funni, Shealeigh A., Dodge, Andrew , Kurani, Shaheen , Shah, Nilay D. , Kurani, Shaheen S, Galindo, Rodolfo J , Ali, Mohammed K , Umpierrez, Guillermo E. , McCoy, Rozalina G.

Mayo Clinic

Diabetes Care | November 5, 2021 | Volume: 45 | Issue: 1 | Pages: 100-107

10.2337/dc21-1579 | PMID 34740910 Get It

OBJECTIVE We characterized annual trends of severe hypoglycemic and hyperglycemic crises (diabetic ketoacidosis/hyperglycemic hyperosmolar state) in patients with diabetes and end-stage kidney disease (ESKD). RESEARCH DESIGN AND METHODS This was a nationwide, retrospective study of adults (≥18 years old) with diabetes/ESKD, from the United States Renal Data System registry, between 2013 and 2017. Primary outcome was annual rates of emergency department visits or hospitalizations for hypoglycemic and hyperglycemic crises, reported as number of events/1,000 person-years. Event rates and risk factors were adjusted for patient age, sex, race/ethnicity, dialysis modality, comorbidities, treatment regimen, and U.S. region. RESULTS Among 521,789 adults with diabetes/ESKD (median age 65 years [interquartile range 57–73], 56.1% male, and 46% White), overall adjusted rates of hypoglycemic and hyperglycemic crises were 53.64 and 18.24 per 1,000 person-years, respectively. For both hypoglycemia and hyperglycemia crises, respectively, the risks decreased with age and were lowest in older patients (≥75 vs. 18–44 years old: incidence rate ratio 0.35, 95% CI 0.33–0.37, and 0.03, 0.02–0.03), women (1.09, 1.06–1.12, and 1.44, 1.35–1.54), and those with smoking (1.36, 1.28–1.43, and 1.71, 1.53–1.91), substance abuse (1.27, 1.15–1.42, and 1.53, 1.23–1.9), retinopathy (1.10, 1.06–1.15, and 1.36, 1.26–1.47), and insulin therapy (vs. no therapy; 0.60, 0.59–0.63, and 0.44, 0.39–0.48). For hypoglycemia, specifically, additional risk was conferred by Black race (1.11, 1.08–1.15) and amputation history (1.20, 1.13–1.27). CONCLUSIONS In this nationwide study of patients with diabetes/ESKD, hypoglycemic crises were threefold more common than hyperglycemic crises, greatly exceeding national reports in nondialysis patients with chronic kidney disease. Young, Black, and female patients were disproportionately affected.
Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth
Cook, Danielle , Martin, Timothy D. , Galanko, Joseph A. , Loeza, Gabriela Herrera, Trembath, Dimitri G. , Justilien, Verline , Pickering, Karen , Jarosch, Armin , Jurmeister, Philipp , Waters, Andrew M. , Hibshman, Priya S. , Campbell, Andrew D. , Yeh, Jen Jen , Lee, Michael S. , Fields, Alan P. , Sandler, Robert S. , Sansom, Owen J. , Sers, Christine , Schaefer, Antje , Martin, Timothy D , Trembath, Dimitri G , Justilien, Verline , Pickering, Karen A , Waters, Andrew M , Lee, Michael S , Cox, Adrienne D , Sandler, Robert S , Sansom, Owen J , Sers, Christine , Schaefer, Antje , Kang, Melissa S , Loeza, Gabriela H., Vincent, David F. , Ford, Catriona A. , Keku, Temitope O , Cox, Adrienne D. , Der, Channing J

Mayo Clinic

Cancer Research | November 4, 2021 | Volume: 82 | Issue: 1 | Pages: 90-104

10.1158/0008-5472.can-20-4218 | PMID 34737214 Get It

Abstract ECT2 is an activator of RHO GTPases that is essential for cytokinesis. In addition, ECT2 was identified as an oncoprotein when expressed ectopically in NIH/3T3 fibroblasts. However, oncogenic activation of ECT2 resulted from N-terminal truncation, and such truncated ECT2 proteins have not been found in patients with cancer. In this study, we observed elevated expression of full-length ECT2 protein in preneoplastic colon adenomas, driven by increased ECT2 mRNA abundance and associated with APC tumor-suppressor loss. Elevated ECT2 levels were detected in the cytoplasm and nucleus of colorectal cancer tissue, suggesting cytoplasmic mislocalization as one mechanism of early oncogenic ECT2 activation. Importantly, elevated nuclear ECT2 correlated with poorly differentiated tumors, and a low cytoplasmic:nuclear ratio of ECT2 protein correlated with poor patient survival, suggesting that nuclear and cytoplasmic ECT2 play distinct roles in colorectal cancer. Depletion of ECT2 reduced anchorage-independent cancer cell growth and invasion independent of its function in cytokinesis, and loss of Ect2 extended survival in a KrasG12D Apc-null colon cancer mouse model. Expression of ECT2 variants with impaired nuclear localization or guanine nucleotide exchange catalytic activity failed to restore cancer cell growth or invasion, indicating that active, nuclear ECT2 is required to support tumor progression. Nuclear ECT2 promoted ribosomal DNA transcription and ribosome biogenesis in colorectal cancer. These results support a driver role for both cytoplasmic and nuclear ECT2 overexpression in colorectal cancer and emphasize the critical role of precise subcellular localization in dictating ECT2 function in neoplastic cells. Significance: ECT2 overexpression and mislocalization support its role as a driver in colon cancer that is independent from its function in normal cell cytokinesis.
Combined Drainage and Protocolized Necrosectomy Through a Coaxial Lumen-apposing Metal Stent for Pancreatic Walled-off Necrosis
Dayyeh, Barham K. Abu, Chandrasekhara, Vinay, Shah, Raj J., Easler, Jeffrey J., Storm, Andrew C., Topazian, Mark, Levy, Michael J., Martin, John A., Petersen, Bret T., Takahashi, Naoki, Edmundowicz, Steven, Hammad, Hazem, Wagh, Mihir S., Wani, Sachin, DeWitt, John, Bick, Benjamin, Gromski, Mark, Haddad, Mohammad Al, Sherman, Stuart, Merchant, Ambreen A., Peetermans, Joyce A., Gjata, Ornela, McMullen, Edmund, Willingham, Field F., Takahashi, Naoki , Takahashi, Naoki , Dayyeh, Barham K. Abu, Chandrasekhara, Vinay, Shah, Raj J., Easler, Jeffrey J., Storm, Andrew C., Topazian, Mark, Levy, Michael J., Martin, John A., Petersen, Bret T., Takahashi, Naoki, Edmundowicz, Steven, Hammad, Hazem, Wagh, Mihir S., Wani, Sachin, DeWitt, John, Bick, Benjamin, Gromski, Mark, Haddad, Mohammad Al, Sherman, Stuart, Merchant, Ambreen A., Peetermans, Joyce A., Gjata, Ornela, McMullen, Edmund, Willingham, Field F.

Mayo Clinic

Annals of Surgery | November 4, 2021 | Volume: 277 | Issue: 5 | Pages: e1072-e1080

10.1097/sla.0000000000005274 | PMID 35129503 Get It

Objective: We evaluated a protocolized endoscopic necrosectomy approach with a lumen-apposing metal stent (LAMS) in patients with large symptomatic walled-off pancreatic necrosis (WON) comprising significant necrotic content, with or without infection. Summary Background Data: Randomized trials have shown similar efficacy of endoscopic treatment compared with surgery for infected WON. Design: We conducted a regulatory, prospective, multicenter single-arm clinical trial examining the efficacy and safety of endoscopic ultrasound -guided LAMS with protocolized necrosectomy to treat symptomatic WON ≥6 cm in diameter with >30% solid necrosis. After LAMS placement, protocolized WON assessment was conducted and endoscopic necrosectomy was performed for insufficient WON size reduction and persistent symptoms. Patients with radiographic WON resolution to ≤ 3 cm and/or 60-day LAMS indwell had LAMS removal, then 6-month follow-up. Primary endpoints were probability of radiographic resolution by 60 days and procedure-related serious adverse events. Results: Forty consecutive patients were enrolled September 2018 to March 2020, of whom 27 (67.5%) were inpatients and 19 (47.5%) had clinical evidence of infection at their index procedure. Mean WON size was 15.0 ± 5.6 cm with mean 53.2% ± 16.7% solid necrosis. Radiographic WON resolution was seen in 97.5% (95% CI, 86.8%, 99.9%) by 60 days, without recurrence in 34 patients with 6-month follow-up data. Mean time to radiographic WON resolution was 34.1 ± 16.8 days. Serious adverse events occurred in 3 patients (7.5%), including sepsis, vancomycin-resistant enterococcal bacteremia and shock, and upper gastrointestinal bleeding. There were no procedure-related deaths. Conclusions: Endoscopic ultrasound-guided drainage with protocolized endoscopic necrosectomy to treat large symptomatic or infected walled-off necrotic pancreatic collections was highly effective and safe. Clinicaltrials.-gov no: NCT03525808.
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
Givertz, Michael M. , Shah, Palak , McNulty, Steven E., Anstrom, Kevin J. , Mahr, Claudius , Gupta, Divya , Redfield, Margaret M. , Lala, Anuradha , Desvigne‐Nickens, Patrice , Braunwald, Eugene, Investigators, LIFE, Mohammed, Selma F. , Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H. , Escobar, Nicole, Fink, Maria Cristina Domingues , Cappola, Thomas P. , Sheaffer, Wendy , Reilly, Bonitta, Ferree, J W, Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch, Delucca, Rosemarie, Doddamani, Sanjay , Thomas, B. , Machen, Laurie, Kim, J., Christina, Athas, Lampert, Brent C. , Fontenelle, Cindy, Eiswirth, Clement, Rock, Darlene, Egnaczyk, Gregory F. , Rentas-Sherman, Enya, Barr, Deborah, Damato, Adrianna, Calayo, Christine, Herre, John M. , Carroll, Amanda , Keebler, Mary , Setliff, Bandaa, Gulati, Sanjeev , Winkler, K, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert , Palardy, Maryse , Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas , Seiler, Beverly, Xu, Zi J., Mersola, S., Kransdorf, E. , Fonk, T., Oliveira, Guilherme H., Semenec, Terrence, Leo, Peter , Dunlap, Mark E. , Felker, G. Michael , Taylor, Lacey D., Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas F., Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Dávila‐Román, Víctor G. , Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana , Fitzgerald, Kathleen, Whellan, David J. , Gutierrez, Jonathan, Goldsborough, Yavette, Caikauskaite, Indre, Skopicki, Hal A. , Huggins, Gordon S. , Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L. , Walker, Brandon S. , JOHNSON, J. Y. M., Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha , Gagliardi, A.R.T., Mann, Douglas L. , Vader, Justin M. , Starling, Randall C. , Margulies, Kenneth B. , Kiernan, Michael S. , Lewis, Gregory D. , DeVore, Adam D. , Hernandez, Adrian F. , Braunwald, Eugene , Investigators, LIFE, Aboye, Etsubdink A, Fink, Maria, Ferree, Jenny, Ravichandran, Ashwin Kumar , Herrera, Glenda, Kanwar, Manreet , Williams, Julie , Bhimaraj, Arvind , Lindenfeld, JoAnn , Gordon, Mary Ellen , Gulati, Sanjeev K., Winkler, Krystal, Tang, W.H. Wilson , Gorodeski, Eiran Z. , Norton, Nadine , Nichols, Julie, Taylor, Lacey, Cunningham, Thomas, Dirks, Anne, Wever‐Pinzon, Omar , Gilotra, Nisha A , Walker, Brandon, Henderson, Simmone, Gagliardi, Ann, Shah, Palak

Mayo Clinic

JAMA Cardiology | November 3, 2021 | Volume: 7 | Issue: 1 | Pages: 17

10.1001/jamacardio.2021.4567 | PMID 34730769 Get It

Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology
Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Alexander, Mariam P. , Troost, Jonathan P., Chen, Junbo, Fermin, Damian , Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid, Henderson, Joel , Riella, Leonardo V , Alexander, Mariam P , Fermin, Damian , Beck, Laurence H , Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Troost, Jonathan P., Chen, Junbo, Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid

Mayo Clinic

Journal of the American Society of Nephrology | November 3, 2021 | Volume: 33 | Issue: 1 | Pages: 238-252

10.1681/asn.2021060794 | PMID 34732507 Get It

Significance Statement Although corticosteroids are an effective first-line therapy for minimal change disease, relapse, steroid dependence, and intolerance are common in this podocytopathy of unknown etiology. The efficacy of B cell–targeted therapies in some patients suggests an autoantibody-mediated etiology. This study describes the novel discovery in both adults and children with minimal change disease of autoantibodies targeting nephrin, a critical component of the podocyte slit diaphragm that ensures integrity of the glomerular filtration barrier. This observation aligns with the established proteinuric effect of antinephrin antibodies demonstrated in animal models. These findings identify an important autoimmune mechanism in a subset of patients with minimal change disease and provide a framework for the application and development of precision medicine strategies in this condition. Background Failure of the glomerular filtration barrier, primarily by loss of slit diaphragm architecture, underlies nephrotic syndrome in minimal change disease. The etiology remains unknown. The efficacy of B cell–targeted therapies in some patients, together with the known proteinuric effect of anti-nephrin antibodies in rodent models, prompted us to hypothesize that nephrin autoantibodies may be present in patients with minimal change disease. Methods We evaluated sera from patients with minimal change disease, enrolled in the Nephrotic Syndrome Study Network (NEPTUNE) cohort and from our own institutions, for circulating nephrin autoantibodies by indirect ELISA and by immunoprecipitation of full-length nephrin from human glomerular extract or a recombinant purified extracellular domain of human nephrin. We also evaluated renal biopsies from our institutions for podocyte-associated punctate IgG colocalizing with nephrin by immunofluorescence. Results In two independent patient cohorts, we identified circulating nephrin autoantibodies during active disease that were significantly reduced or absent during treatment response in a subset of patients with minimal change disease. We correlated the presence of these autoantibodies with podocyte-associated punctate IgG in renal biopsies from our institutions. We also identified a patient with steroid-dependent childhood minimal change disease that progressed to end stage kidney disease; she developed a massive post-transplant recurrence of proteinuria that was associated with high pretransplant circulating nephrin autoantibodies. Conclusions Our discovery of nephrin autoantibodies in a subset of adults and children with minimal change disease aligns with published animal studies and provides further support for an autoimmune etiology. We propose a new molecular classification of nephrin autoantibody minimal change disease to serve as a framework for instigation of precision therapeutics for these patients.
Three Signs of a Shortcut: Gastrogastric Fistula Permitting Simple Roux-en-Y Endoscopic Retrograde Cholangiopancreatography
Heinrich, Matthew P. , Storm, Andrew C.

Mayo Clinic

ACG Case Reports Journal | November 3, 2021 | Volume: 8 | Issue: 11 | Pages: e00694

10.14309/crj.0000000000000694 | PMID 34746330 Get It